JP2003531811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003531811A5 JP2003531811A5 JP2000603378A JP2000603378A JP2003531811A5 JP 2003531811 A5 JP2003531811 A5 JP 2003531811A5 JP 2000603378 A JP2000603378 A JP 2000603378A JP 2000603378 A JP2000603378 A JP 2000603378A JP 2003531811 A5 JP2003531811 A5 JP 2003531811A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- polypeptide
- nucleic acid
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 description 500
- 102000004965 antibodies Human genes 0.000 description 208
- 108090001123 antibodies Proteins 0.000 description 208
- 210000004027 cells Anatomy 0.000 description 208
- 229920001850 Nucleic acid sequence Polymers 0.000 description 164
- 150000007523 nucleic acids Chemical group 0.000 description 154
- 239000005557 antagonist Substances 0.000 description 127
- 230000003042 antagnostic Effects 0.000 description 126
- 201000010099 disease Diseases 0.000 description 118
- 125000003275 alpha amino acid group Chemical group 0.000 description 115
- 241000282414 Homo sapiens Species 0.000 description 93
- 239000000203 mixture Substances 0.000 description 85
- 239000000556 agonist Substances 0.000 description 83
- 241000124008 Mammalia Species 0.000 description 78
- 108020004707 nucleic acids Proteins 0.000 description 78
- 230000003511 endothelial Effects 0.000 description 74
- 230000002491 angiogenic Effects 0.000 description 71
- 206010028980 Neoplasm Diseases 0.000 description 70
- 230000000271 cardiovascular Effects 0.000 description 70
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 69
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 62
- 210000001519 tissues Anatomy 0.000 description 59
- 239000002253 acid Substances 0.000 description 57
- 150000001875 compounds Chemical class 0.000 description 57
- 238000000034 method Methods 0.000 description 57
- 239000002773 nucleotide Substances 0.000 description 56
- 125000003729 nucleotide group Chemical group 0.000 description 56
- 230000027455 binding Effects 0.000 description 55
- 230000000694 effects Effects 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 54
- 108090000623 proteins and genes Proteins 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 52
- 238000004166 bioassay Methods 0.000 description 49
- 230000033115 angiogenesis Effects 0.000 description 48
- 230000014509 gene expression Effects 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 47
- 150000001413 amino acids Chemical class 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 42
- 210000002889 Endothelial Cells Anatomy 0.000 description 41
- 239000003814 drug Substances 0.000 description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 40
- 201000011510 cancer Diseases 0.000 description 39
- -1 methylchlothiazide Chemical compound 0.000 description 38
- 239000000523 sample Substances 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 36
- 210000002216 Heart Anatomy 0.000 description 34
- 101700032742 PROC Proteins 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 33
- 230000010261 cell growth Effects 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 32
- 230000012010 growth Effects 0.000 description 32
- 239000002585 base Substances 0.000 description 31
- 102000018358 Immunoglobulins Human genes 0.000 description 30
- 108060003951 Immunoglobulins Proteins 0.000 description 30
- 229940079593 drugs Drugs 0.000 description 30
- 238000005755 formation reaction Methods 0.000 description 29
- 229920002676 Complementary DNA Polymers 0.000 description 28
- 208000010125 Myocardial Infarction Diseases 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 125000000539 amino acid group Chemical group 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 23
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
- 239000000427 antigen Substances 0.000 description 22
- 230000001965 increased Effects 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 21
- 230000035492 administration Effects 0.000 description 20
- 108091007172 antigens Proteins 0.000 description 20
- 102000038129 antigens Human genes 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 210000004204 Blood Vessels Anatomy 0.000 description 19
- 206010020880 Hypertrophy Diseases 0.000 description 18
- 102000005614 monoclonal antibodies Human genes 0.000 description 18
- 108010045030 monoclonal antibodies Proteins 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 230000001225 therapeutic Effects 0.000 description 18
- 206010007554 Cardiac failure Diseases 0.000 description 17
- 206010007559 Cardiac failure congestive Diseases 0.000 description 17
- 206010019280 Heart failure Diseases 0.000 description 17
- 230000000747 cardiac effect Effects 0.000 description 17
- 201000006233 congestive heart failure Diseases 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 210000000988 Bone and Bones Anatomy 0.000 description 16
- 108020004999 Messenger RNA Proteins 0.000 description 16
- 230000002708 enhancing Effects 0.000 description 16
- 230000001939 inductive effect Effects 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 16
- 229920002106 messenger RNA Polymers 0.000 description 16
- 206010020772 Hypertension Diseases 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 210000002435 Tendons Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 230000001177 retroviral Effects 0.000 description 15
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 229920000272 Oligonucleotide Polymers 0.000 description 14
- 230000001809 detectable Effects 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 14
- 210000000663 muscle cells Anatomy 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 230000002792 vascular Effects 0.000 description 14
- 102100015249 VEGFA Human genes 0.000 description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 13
- 108091006028 chimera Proteins 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 210000000107 myocyte Anatomy 0.000 description 13
- 230000004936 stimulating Effects 0.000 description 13
- 208000002780 Macular Degeneration Diseases 0.000 description 12
- 230000036755 cellular response Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 206010064930 Age-related macular degeneration Diseases 0.000 description 11
- 102000002045 Endothelin Human genes 0.000 description 11
- 108050009340 Endothelin Proteins 0.000 description 11
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 11
- 210000003041 Ligaments Anatomy 0.000 description 11
- 239000004037 angiogenesis inhibitor Substances 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000004881 tumor cells Anatomy 0.000 description 11
- 230000029663 wound healing Effects 0.000 description 11
- 210000001367 Arteries Anatomy 0.000 description 10
- 210000000349 Chromosomes Anatomy 0.000 description 10
- 210000003038 Endothelium Anatomy 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 230000035693 Fab Effects 0.000 description 10
- 101710039937 PFN2 Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003937 drug carrier Substances 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 230000001404 mediated Effects 0.000 description 10
- 239000005541 ACE inhibitor Substances 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 9
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000002759 chromosomal Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 230000000295 complement Effects 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 230000000875 corresponding Effects 0.000 description 9
- 230000003899 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- 201000010238 heart disease Diseases 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 210000004962 mammalian cells Anatomy 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000006011 modification reaction Methods 0.000 description 9
- 229960000060 monoclonal antibodies Drugs 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000017423 tissue regeneration Effects 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- 206010000891 Acute myocardial infarction Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 210000004369 Blood Anatomy 0.000 description 8
- 210000000845 Cartilage Anatomy 0.000 description 8
- 229920001405 Coding region Polymers 0.000 description 8
- 206010020871 Hypertrophic cardiomyopathy Diseases 0.000 description 8
- 206010022114 Injury Diseases 0.000 description 8
- 206010029113 Neovascularisation Diseases 0.000 description 8
- 101710039939 PFN3 Proteins 0.000 description 8
- 101710039926 PFN4 Proteins 0.000 description 8
- 101710018209 PRF4 Proteins 0.000 description 8
- 101710018211 PRF5 Proteins 0.000 description 8
- 101700071719 PRO3 Proteins 0.000 description 8
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 8
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 8
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 8
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 230000008506 pathogenesis Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 229960000187 tissue plasminogen activator Drugs 0.000 description 8
- 201000011528 vascular disease Diseases 0.000 description 8
- 230000002861 ventricular Effects 0.000 description 8
- 230000003612 virological Effects 0.000 description 8
- 108020005544 Antisense RNA Proteins 0.000 description 7
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 102000014429 Insulin-like growth factor Human genes 0.000 description 7
- 108050003490 Insulin-like growth factor Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 210000004413 Myocytes, Cardiac Anatomy 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000001413 cellular Effects 0.000 description 7
- 230000001684 chronic Effects 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002255 enzymatic Effects 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 201000011066 hemangioma Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 229920000023 polynucleotide Polymers 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- 200000000019 wound Diseases 0.000 description 7
- 108020004491 Antisense DNA Proteins 0.000 description 6
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 6
- 206010002906 Aortic stenosis Diseases 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 206010012601 Diabetes mellitus Diseases 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- 210000004072 Lung Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003816 antisense DNA Substances 0.000 description 6
- 229920002847 antisense RNA Polymers 0.000 description 6
- 201000001320 atherosclerosis Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229960000830 captopril Drugs 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000003915 cell function Effects 0.000 description 6
- 230000001419 dependent Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 239000003966 growth inhibitor Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 230000002107 myocardial Effects 0.000 description 6
- 230000001575 pathological Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000004083 survival Effects 0.000 description 6
- 230000002459 sustained Effects 0.000 description 6
- 230000001131 transforming Effects 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- WWSWYXNVCBLWNZ-CHPNCWRZSA-N (Z)-7-[(1S,2S,3S,5R)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C([C@@H](O)\C=C\[C@H]1[C@@H]([C@H](O)C[C@@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-CHPNCWRZSA-N 0.000 description 5
- 210000000709 Aorta Anatomy 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 210000004351 Coronary Vessels Anatomy 0.000 description 5
- 229940030606 DIURETICS Drugs 0.000 description 5
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 5
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 5
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 210000001365 Lymphatic Vessels Anatomy 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 5
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 5
- 210000003462 Veins Anatomy 0.000 description 5
- 230000001058 adult Effects 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 230000001396 anti-anti-diuretic Effects 0.000 description 5
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 5
- 239000002876 beta blocker Substances 0.000 description 5
- 201000009030 carcinoma Diseases 0.000 description 5
- 210000002317 cardiac myocyte Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229960005188 collagen Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 230000000534 elicitor Effects 0.000 description 5
- 229950009951 fluprostenol Drugs 0.000 description 5
- 229940020899 hematological Enzymes Drugs 0.000 description 5
- 230000000004 hemodynamic Effects 0.000 description 5
- 230000001969 hypertrophic Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 230000002188 osteogenic Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 230000002335 preservative Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000003352 sequestering agent Substances 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000000472 traumatic Effects 0.000 description 5
- 239000011778 trisodium citrate Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102100001997 CTF1 Human genes 0.000 description 4
- 210000001736 Capillaries Anatomy 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 210000002808 Connective Tissue Anatomy 0.000 description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 101700058973 GAL4 Proteins 0.000 description 4
- 230000036499 Half live Effects 0.000 description 4
- 206010020718 Hyperplasia Diseases 0.000 description 4
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 4
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 101710015850 LGALS4 Proteins 0.000 description 4
- 102100011539 LGALS4 Human genes 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 210000002751 Lymph Anatomy 0.000 description 4
- 206010025650 Malignant melanoma Diseases 0.000 description 4
- 210000003205 Muscles Anatomy 0.000 description 4
- 210000004165 Myocardium Anatomy 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 229960001597 Nifedipine Drugs 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 101710034683 Pput_4291 Proteins 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 231100000765 Toxin Toxicity 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000002399 angioplasty Methods 0.000 description 4
- 230000003276 anti-hypertensive Effects 0.000 description 4
- 230000000692 anti-sense Effects 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 108010041776 cardiotrophin 1 Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002860 competitive Effects 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 101700081494 degP Proteins 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000003205 diastolic Effects 0.000 description 4
- 229960004166 diltiazem Drugs 0.000 description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 description 4
- 101700030421 fhuA Proteins 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000003054 hormonal Effects 0.000 description 4
- 230000002055 immunohistochemical Effects 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000000302 ischemic Effects 0.000 description 4
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000001402 polyadenylating Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001737 promoting Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 201000004681 psoriasis Diseases 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 229920002033 ribozyme Polymers 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960000103 thrombolytic agents Drugs 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 108020003112 toxins Proteins 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 229960001722 verapamil Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BIDNLKIUORFRQP-XYGFDPSESA-N (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- PXGPLTODNUVGFL-YNNPMVKQSA-N 9α,11α-PGF2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- GOEMGAFJFRBGGG-UHFFFAOYSA-N Acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 3
- 206010002383 Angina pectoris Diseases 0.000 description 3
- 229960002274 Atenolol Drugs 0.000 description 3
- NWIUTZDMDHAVTP-UHFFFAOYSA-N Betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 3
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000008787 Cardiovascular Disease Diseases 0.000 description 3
- LWAFSWPYPHEXKX-UHFFFAOYSA-N Carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 3
- 229960001222 Carteolol Drugs 0.000 description 3
- 210000003917 Chromosomes, Human Anatomy 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 3
- 229960001334 Corticosteroids Drugs 0.000 description 3
- 102100005838 DHFR Human genes 0.000 description 3
- 101710007887 DHFR Proteins 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 3
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 3
- 108010061435 Enalapril Proteins 0.000 description 3
- 229960000873 Enalapril Drugs 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N Endothelin I Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N 0.000 description 3
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 3
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 3
- 229960002949 Fluorouracil Drugs 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 3
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 3
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 3
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 108010007859 Lisinopril Proteins 0.000 description 3
- 229960002394 Lisinopril Drugs 0.000 description 3
- 206010025219 Lymphangioma Diseases 0.000 description 3
- 206010025226 Lymphangitis Diseases 0.000 description 3
- 208000002502 Lymphedema Diseases 0.000 description 3
- 206010025282 Lymphoedema Diseases 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 3
- 229960002237 Metoprolol Drugs 0.000 description 3
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 3
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 3
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 3
- 229960004255 Nadolol Drugs 0.000 description 3
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 3
- 229960001783 Nicardipine Drugs 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- KQXKVJAGOJTNJS-HNNXBMFYSA-N Penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 3
- 229960003401 Ramipril Drugs 0.000 description 3
- 208000003782 Raynaud Disease Diseases 0.000 description 3
- 210000001567 Regular cardiac muscle cell of ventricle Anatomy 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 206010038932 Retinopathy Diseases 0.000 description 3
- 206010038934 Retinopathy proliferative Diseases 0.000 description 3
- 230000036191 S Phase Effects 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 3
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229940104230 Thymidine Drugs 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229960004530 benazepril Drugs 0.000 description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N benzazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229960004324 betaxolol Drugs 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 201000011231 colorectal cancer Diseases 0.000 description 3
- 230000002596 correlated Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 229940000406 drug candidates Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 201000008808 fibrosarcoma Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960002490 fosinopril Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 229960002003 hydrochlorothiazide Drugs 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000977 initiatory Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
- 201000003142 neovascular glaucoma Diseases 0.000 description 3
- 201000008026 nephroblastoma Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229960002035 penbutolol Drugs 0.000 description 3
- 230000002093 peripheral Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 108091008117 polyclonal antibodies Proteins 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- 229960003712 propranolol Drugs 0.000 description 3
- 200000000008 restenosis Diseases 0.000 description 3
- 230000003248 secreting Effects 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229960004605 timolol Drugs 0.000 description 3
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102000035402 transmembrane proteins Human genes 0.000 description 3
- 108091005683 transmembrane proteins Proteins 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-Phosphoglyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710028796 ALDH18A1 Proteins 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N Acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 2
- 208000009956 Adenocarcinoma Diseases 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 229950006323 Angiotensin ii Drugs 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 210000000702 Aorta, Abdominal Anatomy 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010051113 Arterial restenosis Diseases 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 2
- 102400001289 Atrial natriuretic peptide Human genes 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 206010004161 Basedow's disease Diseases 0.000 description 2
- 229960003872 Benzethonium Drugs 0.000 description 2
- NDTSRXAMMQDVSW-UHFFFAOYSA-N Benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 101700036312 CONA Proteins 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 210000002421 Cell Wall Anatomy 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229960002155 Chlorothiazide Drugs 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 102000002585 Contractile Proteins Human genes 0.000 description 2
- 108010068426 Contractile Proteins Proteins 0.000 description 2
- 210000004087 Cornea Anatomy 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 229960000633 Dextran Sulfate Drugs 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 229960004706 Dichlorphenamide Drugs 0.000 description 2
- GJQPMPFPNINLKP-UHFFFAOYSA-N Diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 2
- 108010070600 EC 5.3.1.9 Proteins 0.000 description 2
- 102100010813 EGF Human genes 0.000 description 2
- 101700033006 EGF Proteins 0.000 description 2
- 102000027760 ERBB2 Human genes 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 2
- 108010066668 ErbB-2 Receptor Proteins 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 210000002744 Extracellular Matrix Anatomy 0.000 description 2
- 210000003414 Extremities Anatomy 0.000 description 2
- 101700053597 FCER2 Proteins 0.000 description 2
- 102100014608 FCER2 Human genes 0.000 description 2
- 229950003499 FIBRIN Drugs 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 101710008404 GAPDH Proteins 0.000 description 2
- 102100008842 GH1 Human genes 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 208000005017 Glioblastoma Diseases 0.000 description 2
- 229960002449 Glycine Drugs 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 210000002397 Granulocyte Precursor Cells Anatomy 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 201000004779 Graves' disease Diseases 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 210000001308 Heart Ventricles Anatomy 0.000 description 2
- 206010067660 Heart valve incompetence Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 210000004754 Hybrid Cells Anatomy 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- DMDGGSIALPNSEE-UHFFFAOYSA-N Hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010061255 Ischaemia Diseases 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 2
- 208000001083 Kidney Disease Diseases 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000235651 Lachancea waltii Species 0.000 description 2
- 206010049694 Left ventricular dysfunction Diseases 0.000 description 2
- 206010024190 Leiomyosarcomas Diseases 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000004324 Lymphatic System Anatomy 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 230000035779 M Phase Effects 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000006395 Meigs Syndrome Diseases 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229960004452 Methionine Drugs 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 210000003365 Myofibrils Anatomy 0.000 description 2
- 102000016349 Myosin Light Chains Human genes 0.000 description 2
- 108010067385 Myosin Light Chains Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 108009000551 Nephrotic syndrome Proteins 0.000 description 2
- 206010029331 Neuropathy peripheral Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 101710018198 PRF2 Proteins 0.000 description 2
- 101700074849 PRO2 Proteins 0.000 description 2
- 101700027237 PROA Proteins 0.000 description 2
- 101710033550 PSMB4 Proteins 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 241000282520 Papio Species 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- 206010034636 Peripheral vascular disease Diseases 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 Phenylephrine Drugs 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 208000002151 Pleural Effusion Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 2
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229960000856 Protein C Drugs 0.000 description 2
- 102000001253 Protein Kinases Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 210000001147 Pulmonary Artery Anatomy 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 2
- 206010038436 Renal failure acute Diseases 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 229960005202 Streptokinase Drugs 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 210000002820 Sympathetic Nervous System Anatomy 0.000 description 2
- 101700038204 TGFA Proteins 0.000 description 2
- 102100008604 TYMP Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 101710018080 ThorAB25_04690 Proteins 0.000 description 2
- 229920000401 Three prime untranslated region Polymers 0.000 description 2
- 108091000099 Thymidine Phosphorylase Proteins 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 2
- 101710042194 Trpgamma Proteins 0.000 description 2
- 206010068760 Ulcers Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasm Diseases 0.000 description 2
- 229960005356 Urokinase Drugs 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 208000008383 Wilms Tumor Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 229960001541 benzthiazide Drugs 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000001588 bifunctional Effects 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000006143 cell culture media Substances 0.000 description 2
- 201000001084 cerebrovascular disease Diseases 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic Effects 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 201000009273 endometriosis Diseases 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 101700068005 hbhA Proteins 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002209 hydrophobic Effects 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004041 inotropic agent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000002438 mitochondrial Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 210000002569 neurons Anatomy 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 101700054060 phoA Proteins 0.000 description 2
- 101710016966 phoA2 Proteins 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 101700034429 prsG Proteins 0.000 description 2
- 101700032180 psaA Proteins 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 108091007521 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 201000011056 retinal disease Diseases 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000018448 secretion by cell Effects 0.000 description 2
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 200000000009 stenosis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 201000005060 thrombophlebitis Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 201000011531 vascular cancer Diseases 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- BIGBDMFRWJRLGJ-OXAWKVHCSA-N (1Z,4Z)-3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound N#[N+]\C=C(/[O-])C(C(\[O-])=C\[N+]#N)CC1=CC=CC=C1 BIGBDMFRWJRLGJ-OXAWKVHCSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N (2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-3-hydroxypropanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2S)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- INAPMGSXUVUWAF-XCMZKKERSA-N 1D-myo-inositol 6-phosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-XCMZKKERSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(Z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-Hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 102100016908 ACKR1 Human genes 0.000 description 1
- 101700080270 ADH2 Proteins 0.000 description 1
- 101700012170 ADH5 Proteins 0.000 description 1
- 101700033574 ADH6 Proteins 0.000 description 1
- 102100008450 AFP Human genes 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 description 1
- 101700084127 AVP Proteins 0.000 description 1
- 102100017238 AVP Human genes 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 102000017910 Adrenergic receptor family Human genes 0.000 description 1
- 108060003345 Adrenergic receptor family Proteins 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 108050008484 Alpha tubulin Proteins 0.000 description 1
- 102000000132 Alpha tubulin Human genes 0.000 description 1
- 229940063655 Aluminum stearate Drugs 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N Arabitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- PMGDADKJMCOXHX-BQBZGAKWSA-N Arg-Gln Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O PMGDADKJMCOXHX-BQBZGAKWSA-N 0.000 description 1
- 206010003230 Arteritis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- NPDLYUOYAGBHFB-UHFFFAOYSA-N Asparaginyl-Arginine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N NPDLYUOYAGBHFB-UHFFFAOYSA-N 0.000 description 1
- QJMCHPGWFZZRID-UHFFFAOYSA-N Asparaginyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC(N)=O QJMCHPGWFZZRID-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003658 Atrial fibrillation Diseases 0.000 description 1
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- HZZGDPLAJHVHSP-GKHTVLBPSA-N Big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000002459 Blastocyst Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000701922 Bovine parvovirus Species 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000000409 Breast Neoplasms Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- 101700038590 CCN1 Proteins 0.000 description 1
- 101000560403 CCN2 Proteins 0.000 description 1
- 101700026049 CCN2 Proteins 0.000 description 1
- 102100016705 COL18A1 Human genes 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N CTK2H8874 Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 101710022848 CYPADH Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004040 Capsid Proteins Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 206010007541 Cardiac disease Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 208000002382 Cardiomyopathy, Hypertrophic, Familial Diseases 0.000 description 1
- 208000003295 Carpal Tunnel Syndrome Diseases 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 210000001612 Chondrocytes Anatomy 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 210000003161 Choroid Anatomy 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- 229920001972 Concatemer Polymers 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 210000001787 Dendrites Anatomy 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N Disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 1
- 102000013009 EC 2.7.1.40 Human genes 0.000 description 1
- 108020005115 EC 2.7.1.40 Proteins 0.000 description 1
- 108010011939 EC 4.1.1.1 Proteins 0.000 description 1
- 102000012288 EC 4.2.1.11 Human genes 0.000 description 1
- 108010022181 EC 4.2.1.11 Proteins 0.000 description 1
- 102000005731 EC 5.3.1.9 Human genes 0.000 description 1
- 102100004921 EDN1 Human genes 0.000 description 1
- 102100014111 EDN3 Human genes 0.000 description 1
- 101710005263 EEF1G Proteins 0.000 description 1
- 102100005930 EEF1G Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 101700032127 ETX1 Proteins 0.000 description 1
- 101700029730 ETX2 Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014665 Endocarditis Diseases 0.000 description 1
- 210000001174 Endocardium Anatomy 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- MLFJHYIHIKEBTQ-IYRKOGFYSA-N Endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 1
- 102000010180 Endothelin Receptors Human genes 0.000 description 1
- 108050001739 Endothelin Receptors Proteins 0.000 description 1
- 102000013128 Endothelin receptor B Human genes 0.000 description 1
- 108010090557 Endothelin receptor B Proteins 0.000 description 1
- 108010072834 Endothelin-1 Proteins 0.000 description 1
- 102000003965 Endothelin-2 Human genes 0.000 description 1
- 108090000387 Endothelin-2 Proteins 0.000 description 1
- 108010072844 Endothelin-3 Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 231100000655 Enterotoxin Toxicity 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N Esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 240000006570 Euonymus japonicus Species 0.000 description 1
- 235000016796 Euonymus japonicus Nutrition 0.000 description 1
- 108050001049 Extracellular protein Proteins 0.000 description 1
- 102100007155 FGF1 Human genes 0.000 description 1
- 101700064732 FGF1 Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 210000002458 Fetal Heart Anatomy 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- 102100006425 GAPDH Human genes 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 102100018768 GPI Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 208000002907 Heart Valve Disease Diseases 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000006359 Hepatoblastoma Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000005548 Hexokinases Human genes 0.000 description 1
- 108020002022 Hexokinases Proteins 0.000 description 1
- LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108090000539 Immunoglobulin Isotypes Proteins 0.000 description 1
- 102000004090 Immunoglobulin Isotypes Human genes 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N Indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 Indapamide Drugs 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 210000004969 Inflammatory Cells Anatomy 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- 201000007313 Kawasaki disease Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 210000001117 Keloid Anatomy 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108060004448 LPP Proteins 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940087857 Lupron Drugs 0.000 description 1
- 208000010447 Lymphatic Disease Diseases 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- 206010062198 Microangiopathy Diseases 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000003470 Mitochondria Anatomy 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 description 1
- 208000001089 Multiple System Atrophy Diseases 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 210000004898 N-terminal fragment Anatomy 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 210000000944 Nerve Tissue Anatomy 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000000919 Neurocutaneous Syndrome Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N Nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 description 1
- 229960005425 Nitrendipine Drugs 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 210000003463 Organelles Anatomy 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 229940043515 Other immunoglobulins in ATC Drugs 0.000 description 1
- 206010033266 Ovarian hyperstimulation syndrome Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 101710042135 PPi-PFK Proteins 0.000 description 1
- 102100010734 PRL Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 102000016387 Pancreatic Elastase Human genes 0.000 description 1
- 108010067372 Pancreatic Elastase Proteins 0.000 description 1
- 108020002230 Pancreatic ribonucleases Proteins 0.000 description 1
- 102000005891 Pancreatic ribonucleases Human genes 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 229950009506 Penicillinase Drugs 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000008494 Pericarditis Diseases 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010011302 Peripheral nerve injury Diseases 0.000 description 1
- 206010034606 Peripheral neuropathy Diseases 0.000 description 1
- JWBLQDDHSDGEGR-DRZSPHRISA-N Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 JWBLQDDHSDGEGR-DRZSPHRISA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N Phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229950008882 Polysorbate Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 210000004258 Portal System Anatomy 0.000 description 1
- 229940069338 Potassium Sorbate Drugs 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 229950008679 Protamine sulfate Drugs 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000029610 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N Quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 210000002254 Renal Artery Anatomy 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 206010072736 Rheumatic disease Diseases 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 210000002235 Sarcomeres Anatomy 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PPQRSMGDOHLTBE-UWVGGRQHSA-N Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PPQRSMGDOHLTBE-UWVGGRQHSA-N 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 210000000587 Skeletal Muscle Fibers Anatomy 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 206010061367 Spinal cord disease Diseases 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 208000004841 Squamous Cell Neoplasms Diseases 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000004304 Subcutaneous Tissue Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 241000985696 Tecoma Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000009056 Telangiectasis Diseases 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 208000001608 Teratocarcinoma Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- AUEJLPRZGVVDNU-STQMWFEESA-N Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-STQMWFEESA-N 0.000 description 1
- 101700019707 UBA1 Proteins 0.000 description 1
- 210000003606 Umbilical Veins Anatomy 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 240000004652 Vaccinium ovalifolium Species 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 101710010750 XV Proteins 0.000 description 1
- 101710033807 XVI Proteins 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-J aluminum;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-J 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 201000003076 angiosarcoma Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002236 anti-hypertrophic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 201000004914 benign vascular tumor Diseases 0.000 description 1
- VKTKKIUJXDETTR-UHFFFAOYSA-N benzene-1,3-diol;cyclopentanol Chemical compound OC1CCCC1.OC1=CC=CC(O)=C1 VKTKKIUJXDETTR-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108020004256 beta-Lactamases Proteins 0.000 description 1
- 102000006635 beta-Lactamases Human genes 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 101710023118 btfP Proteins 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000003177 cardiotonic Effects 0.000 description 1
- 230000003548 cardiotrophic Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000005262 chondroma Diseases 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 201000006617 congenital myasthenic syndrome 21 Diseases 0.000 description 1
- 201000006625 congenital myasthenic syndrome 5 Diseases 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 201000000057 coronary stenosis Diseases 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000001351 cycling Effects 0.000 description 1
- 230000001085 cytostatic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RMQKPRRJSKFBRU-UHFFFAOYSA-N ethyl 2-[2-(diethylamino)ethylcarbamoyl]-2-phenylbutanoate Chemical compound CCN(CC)CCNC(=O)C(CC)(C(=O)OCC)C1=CC=CC=C1 RMQKPRRJSKFBRU-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000006692 familial hypertrophic cardiomyopathy Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000003176 fibrotic Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 108060003196 globin family Proteins 0.000 description 1
- 102000018146 globin family Human genes 0.000 description 1
- 201000005618 glomus tumor Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023560 heart growth Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 102000021184 human CCN2 protein Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000001631 hypertensive Effects 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 108010091798 leucylleucine Proteins 0.000 description 1
- 210000004523 ligament cell Anatomy 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000000492 lymphangiogenic Effects 0.000 description 1
- 201000002135 lymphatic system disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 108040009853 metal chelating activity proteins Proteins 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N methanoic acid amidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229950006804 methylclothiazide Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108060005018 mobB Proteins 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001016 myotrophic Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000001452 natriuretic Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 201000010133 oligodendroglioma Diseases 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 101700002291 ompT Proteins 0.000 description 1
- 230000000771 oncological Effects 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001991 pathophysiological Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 201000008838 periodontal disease Diseases 0.000 description 1
- 230000002572 peristaltic Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 101710036149 pfk-1.2 Proteins 0.000 description 1
- 101700087004 pfkA1 Proteins 0.000 description 1
- 101700035696 pfkB Proteins 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108010084572 phenylalanyl-valine Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000031055 positive regulation of mitosis Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-M propanimidate Chemical compound CCC([O-])=N QLNJFJADRCOGBJ-UHFFFAOYSA-M 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000001698 pyrogenic Effects 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001172 regenerating Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000003252 repetitive Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000552 rheumatic Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000004905 short-term response Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000002889 sympathetic Effects 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100001005 telangiectasia Toxicity 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000002537 thrombolytic Effects 0.000 description 1
- 230000002992 thymic Effects 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 108091006090 transcriptional activators Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000004642 transportation engineering Methods 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 101710028286 valS Proteins 0.000 description 1
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000000033 vasopressor Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Images
Applications Claiming Priority (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9905028 | 1999-03-08 | ||
| PCT/US1999/005028 WO1999046281A2 (fr) | 1998-03-10 | 1999-03-08 | Nouveaux polypeptides et acides nucleiques les codant |
| US12395799P | 1999-03-12 | 1999-03-12 | |
| US60/123,957 | 1999-03-12 | ||
| US9912252 | 1999-06-02 | ||
| PCT/US1999/012252 WO1999063088A2 (fr) | 1998-06-02 | 1999-06-02 | Proteines membranaires et acides nucleiques codant ces proteines |
| US14475899P | 1999-07-20 | 1999-07-20 | |
| US60/144,758 | 1999-07-20 | ||
| US14569899P | 1999-07-26 | 1999-07-26 | |
| US60/145,698 | 1999-07-26 | ||
| PCT/US1999/020111 WO2000012708A2 (fr) | 1998-09-01 | 1999-09-01 | Nouveaux pro-polypeptides et sequences correspondantes |
| US9920111 | 1999-09-01 | ||
| PCT/US1999/021090 WO2000015796A2 (fr) | 1998-09-16 | 1999-09-15 | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides |
| US9921090 | 1999-09-15 | ||
| PCT/US1999/028313 WO2000032221A2 (fr) | 1998-12-01 | 1999-11-30 | Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque |
| US9928313 | 1999-11-30 | ||
| PCT/US1999/028409 WO2000032778A2 (fr) | 1998-12-01 | 1999-11-30 | Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques |
| US9928409 | 1999-11-30 | ||
| US9928565 | 1999-12-02 | ||
| PCT/US1999/028565 WO2000037638A2 (fr) | 1998-12-22 | 1999-12-02 | Methodes permettant d'inhiber la croissance de cellules neoplasiques |
| PCT/US2000/000219 WO2000053753A2 (fr) | 1999-03-08 | 2000-01-05 | Activation ou inhibition de l'angiogenese et de la cardiovascularisation |
| US0000219 | 2000-01-05 | ||
| US0004341 | 2000-02-18 | ||
| PCT/US2000/004341 WO2000053756A2 (fr) | 1999-03-08 | 2000-02-18 | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
| PCT/US2000/004342 WO2000078961A1 (fr) | 1999-06-23 | 2000-02-18 | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides |
| US0004342 | 2000-02-18 | ||
| US0004414 | 2000-02-22 | ||
| PCT/US2000/004414 WO2001004311A1 (fr) | 1999-07-07 | 2000-02-22 | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides |
| PCT/US2000/005004 WO2000053757A2 (fr) | 1999-03-08 | 2000-02-24 | Activation et inhibition de l'angiogenese et de la cardiovascularisation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003420475A Division JP2004154140A (ja) | 1999-03-08 | 2003-12-18 | 血管形成及び心血管新生の促進又は阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003531811A JP2003531811A (ja) | 2003-10-28 |
| JP2003531811A5 true JP2003531811A5 (fr) | 2007-04-12 |
Family
ID=30773423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000603378A Pending JP2003531811A (ja) | 1999-03-08 | 2000-02-24 | 血管形成及び心臓血管新生の促進又は阻害 |
| JP2003420475A Pending JP2004154140A (ja) | 1999-03-08 | 2003-12-18 | 血管形成及び心血管新生の促進又は阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003420475A Pending JP2004154140A (ja) | 1999-03-08 | 2003-12-18 | 血管形成及び心血管新生の促進又は阻害 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1159419A1 (fr) |
| JP (2) | JP2003531811A (fr) |
| KR (2) | KR100553300B1 (fr) |
| AU (1) | AU768694B2 (fr) |
| CA (1) | CA2361849A1 (fr) |
| WO (1) | WO2000053757A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6590088B1 (en) | 1996-07-19 | 2003-07-08 | Human Genome Sciences, Inc. | CD33-like protein |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6511834B1 (en) | 2000-03-24 | 2003-01-28 | Millennium Pharmaceuticals, Inc. | 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor |
| US6627423B2 (en) | 2000-03-24 | 2003-09-30 | Millennium Pharmaceuticals, Inc. | 21481, a novel dehydrogenase molecule and uses therefor |
| JP5105696B2 (ja) | 2001-11-16 | 2012-12-26 | ジェネンテック， インコーポレイテッド | アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2006223579A1 (en) * | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
| CA2658618A1 (fr) * | 2006-07-28 | 2008-04-10 | Genentech, Inc. | Nouvelles disruptions geniques, compositions et procedes correspondants |
| KR20160015403A (ko) | 2009-07-14 | 2016-02-12 | 더 스크립스 리서치 인스티튜트 | 중간엽 줄기 세포 분화 |
| WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
| MA38369B1 (fr) | 2013-03-08 | 2018-10-31 | Novartis Ag | Peptides et compositions pour le traitement d'une lesion de l'articulation |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| CN112837306B (zh) * | 2021-02-20 | 2022-11-22 | 薛竟宜 | 基于深度学习和中智理论的冠状动脉病变功能学定量方法 |
| CN117054652B (zh) * | 2023-08-04 | 2024-05-17 | 南京医科大学 | 一种用于辅助检测心肌肥厚的生物标志物及其应用 |
| CN117982987B (zh) * | 2024-04-03 | 2024-06-18 | 四川厚浦生物科技有限公司 | 一种白细胞过滤材料及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900673A (en) * | 1988-03-28 | 1990-02-13 | President And Fellows Of Harvard College | Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression |
| US5885795A (en) * | 1994-04-26 | 1999-03-23 | The Children's Medical Center Corporation | Methods of expressing angiostatic protein |
| US6057435A (en) * | 1997-09-19 | 2000-05-02 | Genentech, Inc. | Tie ligand homologues |
| US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| WO1999055869A1 (fr) * | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Nouveaux facteurs et materiels de croissance polypeptidiques et leurs procedes de production |
| EP1078046A4 (fr) * | 1998-05-12 | 2005-05-11 | Human Genome Sciences Inc | 97 proteines humaines secretees |
| SV1999000069A (es) * | 1998-06-02 | 2000-04-11 | Lilly Co Eli | Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261 |
| WO1999067382A2 (fr) * | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Sequences d'un facteur de croissance apparente a l'angiopoietine |
| JP2007222001A (ja) * | 1998-11-17 | 2007-09-06 | Sagami Chem Res Center | 疎水性ドメインを有するヒトタンパク質及びそれをコードするｄｎａ |
| ATE458050T1 (de) * | 1998-12-01 | 2010-03-15 | Genentech Inc | Promotion oder inhibition von angiogenese und kardiovaskularisation |
| EP1141284A2 (fr) * | 1998-12-22 | 2001-10-10 | Genentech, Inc. | Methodes permettant d'inhiber la croissance de cellules neoplasiques |
-
2000
- 2000-02-24 AU AU33816/00A patent/AU768694B2/en not_active Ceased
- 2000-02-24 KR KR1020017011378A patent/KR100553300B1/ko not_active IP Right Cessation
- 2000-02-24 WO PCT/US2000/005004 patent/WO2000053757A2/fr active IP Right Grant
- 2000-02-24 JP JP2000603378A patent/JP2003531811A/ja active Pending
- 2000-02-24 CA CA002361849A patent/CA2361849A1/fr not_active Abandoned
- 2000-02-24 EP EP00912015A patent/EP1159419A1/fr not_active Withdrawn
- 2000-02-24 KR KR1020017011378D patent/KR20010104373A/ko unknown
-
2003
- 2003-12-18 JP JP2003420475A patent/JP2004154140A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4358159B2 (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
| KR20010084882A (ko) | 신생 세포 성장을 억제하기 위한 방법 및 조성물 | |
| AU768694B2 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| JP2003531811A5 (fr) | ||
| JP2012246296A (ja) | 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター | |
| JP2009019032A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
| KR100543857B1 (ko) | 혈관신생 및 심혈관형성의 촉진 또는 억제 | |
| EP2042597B1 (fr) | Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse | |
| JP2003524599A (ja) | 血管新生と心血管新生の促進又は阻害 | |
| KR100678523B1 (ko) | Pro840 폴리펩티드 아고니스트 또는 길항제의 확인 방법 | |
| EP1734051A2 (fr) | Composition et procédés de diagnostic de tumeurs | |
| AU2003259607B2 (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| NZ532803A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| ZA200105990B (en) | Promotion or inhibition of angiogenesis and cardiovascularization. | |
| ZA200103707B (en) | Promotion or inhibition of angiogenesis and cardio-vascularization. | |
| NZ540754A (en) | Promotion or inhibition of angiogenesis and cardiovascularization | |
| NZ535590A (en) | Promotion or inhibition of angiogenesis and cardiovascularization |